Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.81 |
| ▸ | NPC1 | O15118 | 5/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | MITF | O75030 | 1/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | SNCA | P37840 | 1/20 | 0.63 |
| ▸ | NOS1 | P29475 | 1/20 | 0.60 |
| ▸ | NOS2 | P35228 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192214 | 1.00 | RAB9A (0.81) | RAB9ANPC1PTPN1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5794257 | 0.98 | RAB9A (0.79) | RAB9ANPC1PTPN1MEN1KMT2A | |
| SCHEMBL15164871 | 0.91 | NPC1 (0.68) | RAB9ANPC1PTPN1MEN1KMT2A | |
| SCHEMBL14580374 | 0.90 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL12310125 | 0.90 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL27181403 | 0.90 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL10684470 | 0.90 | PTPN1 (0.88) | RAB9ANPC1PTPN1MEN1KMT2A | |
| SCHEMBL822378 | 0.90 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL15214321 | 0.90 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL14433920 | 0.86 | PTPN1 (0.69) | RAB9ANPC1PTPN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495475-A | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | claimed |
| EP-2034838-A2 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | claimed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | claimed |
| WO-2007147103-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1865959-A2 | PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | claimed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| CN-115304506-B | Preparation method of secondary amide compound by activating primary amide through boron salt catalysis | 中国人民解放军国防科技大学 | 2023-11-14 | — | — | CN | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-115974711-A | Preparation method of aryl amide compound by using aromatic ester catalytically activated by boron salt | 湖南农业大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-115304506-A | Preparation method of secondary amide compound by activating primary amide under catalysis of boron salt | 中国人民解放军国防科技大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-107628964-B | A kind of synthetic method of N- aryl Zhong Fang amide | 陕西科技大学 | 2019-06-21 | — | — | CN | disclosed |
| CN-101184758-A | Novel compounds | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| WO-2006104915-A9 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LTD (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1865959-A2 | PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | RAB9A 1810/4885NPC1 1422/4885PTPN1 2596/4885 |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | RAB9A 1737/4885NPC1 4045/4885PTPN1 2282/4885 |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | CYP2S1, CYP2F1, CBR3 | RAB9A 1800/4885NPC1 3552/4885PTPN1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.